Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in India

09/19/2021 | 06:30pm EST

ResApp Health Limited announced that it has recruited ten patients on the first day of its pilot study for the collection of cough sounds from patients with suspected COVID-19 in India. ResApp aims to use this data to develop a smartphone-based algorithm to instantly screen for COVID-19 and monitor disease progression. Patient recruitment follows approval from an institutional review board that assessed and approved the ethical design of the study. The study is registered on Clinical Trials Registry ­ India (CTRI/2021/09/036581). ResApp has engaged Triomics, a clinical trial company based in India, to complete the study. The study will collect cough sounds, symptoms, medical history and a COVID-19 polymerase chain reaction (PCR) test result from each participant. The multi-site study will recruit a total of 220 participants across two study arms: 120 individuals who present for outpatient COVID-19 PCR testing and 100 individuals who are COVID-19 positive and are inpatients at a study site. Inpatients will provide cough sound samples at multiple times during their hospital stay. Study recruitment is expected to be complete by the end of October. ResApp is using data collected in this clinical study, as well as its two US studies, to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone.


ę S&P Capital IQ 2021
All news about RESAPP HEALTH LIMITED
11/29RESAPP HEALTH : receives world's first regulatory approvals for cough counter smartphone a..
PU
11/28ResApp Health Secures Australian, European Approvals for Cough Counter App; Shares Rise..
MT
11/28ResApp Receives Regulatory Approvals for Cough Counter
CI
11/23ResApp Health Completes Recruitment for COVID-19 Study in India
MT
11/22RESAPP HEALTH : completes COVID-19 study recruitment in India
PU
11/22ResApp Health Limited Completes COVID-19 Study Recruitment in India
CI
11/18RESAPP HEALTH : New publication highlights challenges of diagnosing acute respiratory dise..
PU
11/18Resapp Health Limited Announces Publication of Clinical Study Data Analysed from its Br..
CI
11/17Resapp Health Signs Deal with Johnson & Johnson Arm for Use of App in a Clinical Trial;..
MT
11/17RESAPP HEALTH : secures contract with global pharmaceutical company
PU
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,74 M -4,74 M
Net cash 2021 6,40 M 4,48 M 4,48 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 51,6 M 36,2 M 36,1 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 80,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-29.41%36
SNAP INC.-6.55%77 125
PERFECT WORLD CO., LTD.-34.81%5 821
KAKAO GAMES CORP.106.96%5 802
GRUBHUB INC.-19.36%5 591
ANGI INC.-30.28%4 622